Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: A randomized phase III trial

Journal of the National Cancer Institute

Volumn 102, Issue 12, 2010, Pages 859-865

  Lu, Charles ^a   Lee, J Jack ^a   Komaki, Ritsuko ^a   Herbst, Roy S ^a   Feng, Lei ^a   Evans, William K ^b   Choy, Hak ^c   Desjardins, Pierre ^d   Esparaz, Benjamin T ^e   Truong, Mylene T ^a   Saxman, Scott ^f   Kelaghan, Joseph ^g   Bleyer, Archie ^a   Fisch, Michael J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d HÔPITAL CHARLES LEMOYNE   (Canada)

^e Decatur Memorial Hospital   (United States)

^f Cancer Therapy Evaluation Program   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AE 941; CARBOPLATIN; CISPLATIN; NAVELBINE; PACLITAXEL; PLACEBO; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; SHARK CARTILAGE EXTRACT; TISSUE EXTRACT;

ADULT; ANEMIA; ARTICLE; CANADA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPNEA; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX; THROMBOCYTOPENIA; UNITED STATES; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; CARTILAGE; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL PRODUCTS; CARCINOMA, NON-SMALL-CELL LUNG; CARTILAGE; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; TISSUE EXTRACTS; TREATMENT OUTCOME;

EID: 77953695968     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq179     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.
2. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer. 1995;75 (1 suppl):191-202.
3. Blackstock AW, Govindan R. Defnitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. J Clin Oncol. 2007;25(26): 4146-4152.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1):57-70.
5. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24): 2542-2550.
6. Gingras D, Boivin D, Deckers C, Gendron S, Barthomeuf C, Beliveau R. Neovastat\a novel antiangiogenic drug for cancer therapy. Anticancer Drugs. 2003;14(2):91-96.
7. Dupont É, Falardeau P, Mousa S, et al. Antiangiogenic and antimetastatic properties of Neovastat (Æ-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis. 2002;19(2):145-153.
8. Boivin D, Gendron S, Beaulieu E, Gingras D, Beliveau R. The antiangio-genic agent Neovastat (Ae-941) induces endothelial cell apoptosis. Mol Cancer Ther. 2002;1(10):795-802.
9. Beliveau R, Gingras D, Kruger EA, et al. The antiangiogenic agent Neovastat (Ae-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin Cancer Res. 2002;8(4):1242-1250.
10. Gingras D, Renaud A, Mousseau N, Beaulieu E, Kachra Z, Beliveau R. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res. 2001;21(1A):145-155.
11. Latreille J, Batist G, Laberge F, et al. Phase I/II trial of the safety and ef-fcacy of AE-941 (Neovastat®) in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2003;4(4):231-236.
12. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer. 1996;32A(7): 1135-1141.
13. National Cancer Institute. Common Toxicity Criteria (CTC) v2.0. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm. Accessed March 30, 2010.
14. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207-214.
15. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-526.
16. Edzard E. The prevalence of complementary/alternative medicine in cancer. Cancer. 1998;83(4):777-782.
17. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000;18(13): 2505-2514.
18. Escudier B, Venner V, Buckowski R, et al. Phase III trial of Neovastat in metastatic renal cell carcinoma patients refractory to immunotherapy. Proc Am Soc Clin Oncol. 2003;22:211. Abstract 844.
19. Aeterna Zentaris Press Release. Æterna Laboratories Reports Phase III Trial Results in Renal Cell Carcinoma with Neovastat. http://www.aetern azentaris.com/en/page.php?p=60&q=46. Accessed September 24, 2003.
20. Loprinzi CL, Levitt R, Barton DL, et al. Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer. 2005;104(1):176-182.
21. Miller DR, Anderson GT, Stark JJ, Granick JL, Richardson D. Phase I/II trial of the safety and effcacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol. 1998;16(11):3649-3655.
22. Heymach JV, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as frst-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008;26(33): 5407-5415.
23. Natale RB, Bodkin D, Govindan R, et al. Vandetanib versus geftinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study. J Clin Oncol. 2009;27(15): 2523-2529.
24. Blumenschein GR Jr, Gatzemeier U, Fossella F, et al. Phase II, multi-center, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(26):4274-4280.
25. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol. 2008;26(4):650-656.
26. Wheatley-Price P, Shepherd FA. Targeting angiogenesis in the treatment of lung cancer. J Thorac Oncol. 2008;3(10):1173-1184.